Clinical Aspects of Gastric Cancer and Helicobacter pylori- Screening, Prevention, and Treatment

Helicobacter

Volumn 15, Issue SUPPL. 1, 2010, Pages 40-45

  Selgrad, Michael ^a   Bornschein, Jan ^a   Rokkas, Theodore ^b   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b HENRY DUNANT HOSPITAL   (Greece)

Author keywords

Chemotherapy; Eradication; New drugs

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; TEGAFUR; TRASTUZUMAB;

ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; ERADICATION THERAPY; FEBRILE NEUTROPENIA; HELICOBACTER INFECTION; HUMAN; INFECTION PREVENTION; INFECTION RISK; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SCREENING TEST; STOMACH CANCER; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MASS SCREENING; STOMACH NEOPLASMS;

HELICOBACTER PYLORI;

EID: 78249276181     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2010.00783.x     Document Type: Article

References (49)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50.
2. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003;95:1784-91.
3. Malfertheiner P, Bornschein J, Selgrad M. Role of Helicobacter pylori infection in gastric cancer pathogenesis: a chance for prevention. J Dig Dis 2010;11:2-11.
4. Yamaoka Y, Kato M, Asaka M. Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med 2008;47:1077-83.
5. Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004;109:138-43.
6. Vaananen H, Vauhkonen M, Helske T, Kaariainen I, Rasmussen M, Tunturi-Hihnala H, et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 2003;15:885-91.
7. Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005;54:764-8.
8. Mizuno S, Miki I, Ishida T, Yoshida M, Onoyama M, Azuma T, et al. Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori Infection and atrophic gastritis. Dig Dis Sci 2010;[Epub ahead of print].
9. Mizuno S, Kobayashi M, Tomita S, Miki I, Masuda A, Onoyama M, et al. Validation of the pepsinogen test method for gastric cancer screening using a follow-up study. Gastric Cancer 2009;12:158-63.
10. Miki K, Fujishiro M, Kodashima S, Yahagi N. Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. Dig Endosc 2009;21:78-81.
11. Ren JS, Kamangar F, Qiao YL, Taylor PR, Liang H, Dawsey SM, et al. Serum pepsinogens and risk of gastric and oesophageal cancers in the general population nutrition intervention trial cohort. Gut 2009;58:636-42.
12. Yamaji Y, Watabe H, Yoshida H, Kawabe T, Wada R, Mitsushima T, et al. High-risk population for gastric cancer development based on serum pepsinogen status and lifestyle factors. Helicobacter 2009;14:81-6.
13. Capelle LG, De Vries AC, Haringsma J, Steyerberg EW, Looman CW, Nagtzaam NM, et al. Serum levels of leptin as marker for patients at high risk of gastric cancer. Helicobacter 2009;14:596-604.
14. Fry LC, Monkemuller K, Malfertheiner P. Prevention of gastric cancer: a challenging but feasible task. Acta Gastroenterol Latinoam 2007;37:110-7.
15. Malfertheiner P, Sipponen P, Naumann M, Moayyedi P, Megraud F, Xiao SD, et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol 2005;100:2100-15.
16. De Vries AC, Kuipers EJ. Review article: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther 2007;26(Suppl 2):25-35.
17. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392-7.
18. Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009;137:1641-8.
19. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009;151:121-8.
20. De Vries AC, Kuipers EJ, Rauws EA. Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn? Am J Gastroenterol 2009;104:1342-5.
21. Fuccio L, Eusebi LH, Zagari RM, Bazzoli F. Helicobacter pylori eradication treatment reduces but does not abolish the risk of gastric cancer. Am J Gastroenterol 2009;104:3100-2.
22. Cannizzaro R, De PP. Helicobacter pylori eradication, endoscopic surveillance, and gastric cancer. Am J Gastroenterol 2009;104:3100-1.
23. Yoshida T, Ono H, Kuchiba A, Saeki N, Sakamoto H. Genome-wide germline analyses on cancer susceptibility and GeMDBJ database: gastric cancer as an example. Cancer Sci 2010;Apr 9. [Epub ahead of print].
24. Yanaoka K, Oka M, Ohata H, Yoshimura N, Deguchi H, Mukoubayashi C, et al. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Int J Cancer 2009;125:2697-703.
25. Rupnow MF, Chang AH, Shachter RD, Owens DK, Parsonnet J. Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States. J Infect Dis 2009;200:1311-7.
26. Del GG, Malfertheiner P, Rappuoli R. Development of vaccines against Helicobacter pylori. Expert Rev Vaccines 2009;8:1037-49.
27. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554-68.
28. Zhang XL, Yang YS, Xu DP, Qu JH, Guo MZ, Gong Y, et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg 2009;33:2112-8.
29. Park SR, Kook MC, Choi IJ, Kim CG, Lee JY, Cho SJ, et al. Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients. Cancer Chemother Pharmacol 2010;65:579-87.
30. Jorgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010;78:26-33.
31. Van Cutsem E, Kang Y, Chung H. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER-2)-positive advanced gastric cancer (GC). (abstract). J Clin Oncol 2009;27: 18s (suppl; abstr LBA4509).
32. Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 2010;17:14-7.
33. Meza-Junco J, Au HJ, Sawyer MB. Trastuzumab for gastric cancer. Expert Opin Biol Ther 2009;9:1543-51.
34. Doi T, Muro K, Boku N, Yamada Y, Nishina T, Takiuchi H, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010;28:1904-10.
35. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;3:358.
36. Okines AF, Norman AR, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009;20:1529-34.
37. Starling N, Rao S, Cunningham D, Iveson T, Nicolson M, Coxon F, et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 2009;27:3786-93.
38. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010;28:1547-53.
39. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009;10:1063-9.
40. Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, et al. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer 2010;116:1446-53.
41. Van Cutsem CE, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-7.
42. Tebbutt NC, Cummins MM, Sourjina T, Strickland A, Van HG, Ganju V, et al. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer 2010;102:475-81.
43. Biffi R, Fazio N, Luca F, Chiappa A, Andreoni B, Zampino MG, et al. Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. World J Gastroenterol 2010;16:868-74.
44. Sakamoto J, Matsui T, Kodera Y. Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer 2009;12:69-78.
45. Bamias A, Karina M, Papakostas P, Kostopoulos I, Bobos M, Vourli G, et al. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol 2010;65:1009-21.
46. Dikken JL, Jansen EP, Cats A, Bakker B, Hartgrink HH, Kranenbarg EM, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol 2010;28:2430-6.
47. Jee YS, Hwang SH, Rao J, Park DJ, Kim HH, Lee HJ, et al. Safety of extended endoscopic mucosal resection and endoscopic submucosal dissection following the Japanese Gastric Cancer Association treatment guidelines. Br J Surg 2009;96:1157-61.
48. Mikami K, Maekawa T, Shinohara T, Hoshino S, Yamauchi Y, Noritomi T, et al. Predictive factors of early recurrent death after a curative resection of gastric cancer. Int Surg 2009;94:144-8.
49. Fareed KR, Ilyas M, Kaye PV, Soomro IN, Lobo DN, Parsons SL, et al. Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy. Histopathology 2009;55:399-406.